Side Effects of Trulicity: Full List, How Often They Happen, and What to Do About Each One

Key Takeaways (4-6 bullets, will render as highlighted box)

• The most common Trulicity (dulaglutide) side effects are nausea (21%), diarrhea (13%), vomiting (13%), abdominal pain (9%), and decreased appetite (9%) per the AWARD trial pooled data.
• About 70% of side effects show up in the first 4 to 8 weeks and resolve as the body adapts.
• Serious but rare risks include pancreatitis, gallbladder disease, severe hypoglycemia (in combination with insulin or sulfonylureas), and a black-box warning for thyroid C-cell tumors based on rodent data.
• Most GI side effects respond to slower titration, smaller meals, hydration, and specific anti-nausea or anti-diarrheal medications.
• Trulicity is the same drug class as semaglutide and tirzepatide, so the side-effect profile is broadly similar with some specific differences in nausea severity and injection-site reactions.

Direct answer (40-60 words)

Trulicity (dulaglutide) is a once-weekly GLP-1 receptor agonist with a side-effect profile dominated by gastrointestinal symptoms: nausea (21%), diarrhea (13%), and vomiting (13%) lead the list per the AWARD trials (Umpierrez et al., Diabetes Care 2014). Most side effects resolve within 8 to 12 weeks. Serious risks include pancreatitis, gallbladder issues, and a thyroid tumor warning based on rodent data.

Table of contents

1. The full side-effect list by frequency
2. What each common side effect actually feels like
3. The 5 serious side effects you cannot ignore
4. Why side effects show up in weeks 2 to 8
5. Working protocols for each common symptom
6. Trulicity vs other GLP-1 medications on side effects
7. Black-box warning: thyroid C-cell tumors
8. Pregnancy, lactation, and special populations
9. Drug interactions worth knowing
10. When to call a provider
11. FAQ

The full side-effect list by frequency

The frequencies below are pooled from the AWARD trial program (Umpierrez et al., Diabetes Care 2014), the FDA prescribing information for Trulicity, and post-marketing surveillance. Frequencies are higher at the 4.5 mg maximum dose than at 0.75 mg starting dose.

Side effect	Approximate frequency	Onset window	Severity
Nausea	21%	Week 1 to 4	Mild to moderate
Diarrhea	13%	Week 1 to 4	Mild
Vomiting	13%	Week 1 to 4	Mild to moderate
Abdominal pain	9%	Week 2 to 6	Mild
Decreased appetite	9%	Week 1 to 4	Mild (often desired)
Dyspepsia	6%	Week 2 to 6	Mild
Fatigue	6%	Week 1 to 4	Mild
Constipation	4%	Week 2 to 8	Mild
Injection-site reaction	1 to 2%	Day 1 to 7	Mild
Hypoglycemia (with insulin or SU)	4 to 10%	Variable	Moderate
Tachycardia (small heart rate increase)	2 to 3%	Variable	Mild
Acute pancreatitis	<0.3%	Variable	Severe
Gallbladder disease	0.3 to 1.5%	Variable	Moderate to severe
Acute kidney injury (often via dehydration)	<1%	Variable	Severe
Severe allergic reaction	<0.1%	Day 1 to 30	Severe
Thyroid C-cell tumors	Theoretical (rodent data)	Long-term	Severe

About 6 to 8% of patients in trials discontinued because of side effects, mostly from persistent nausea and vomiting. The discontinuation rate is comparable to semaglutide and slightly lower than the higher doses of tirzepatide.

What each common side effect actually feels like

Nausea (21%). Often described as a steady "queasy" feeling rather than acute waves. Worse 6 to 24 hours after the weekly injection, then tapering. Often paired with food aversions and a metallic or "off" taste. Most patients describe it as 3 to 5 out of 10 in severity at the worst point.

Diarrhea (13%). Loose, often watery stools, typically 2 to 4 times per day. Worse in week 1 to 2 and during dose escalations. Usually resolves with diet adjustments and time. About 1 in 50 patients has diarrhea severe enough to discontinue.

Vomiting (13%). Often follows large meals, fatty meals, or alcohol. Most patients vomit once per day at most during the bad week, not multiple times. Persistent vomiting more than 24 hours is a red flag (see serious section below).

Abdominal pain (9%). Typically upper abdominal, mid to right side, often after meals. Differs from gallbladder pain (sharper, right upper quadrant, radiating to the shoulder) and from pancreatitis pain (severe, radiating to the back). Mild crampy pain is common and benign in most cases.

Decreased appetite (9%). Most patients welcome this. Hunger waves soften, portion sizes shrink naturally, and food obsession ("food noise") quiets. Becomes problematic only if intake drops below maintenance for more than a week, leading to fatigue, hair loss, or muscle loss.

Dyspepsia (6%). Bloating, fullness, mild upper-abdominal discomfort, sometimes belching. Worse with carbonated beverages, fatty foods, and large meals.

Fatigue (6%). Usually mild, often tied to reduced caloric intake rather than the drug directly. Worsens if hydration drops or if patients skip meals.

Constipation (4%). Less common than diarrhea but can be more persistent. Hard, infrequent stools (less than 3 per week). Often appears after the diarrhea phase resolves and the gut "overcorrects."

Injection-site reaction (1 to 2%). Redness, mild swelling, or itching at the injection site. Usually resolves in 24 to 72 hours. Severe reactions (large hives, persistent pain) are uncommon.

The 5 serious side effects you cannot ignore

These are the side effects that warrant immediate provider contact or emergency care.

1. Acute pancreatitis (<0.3%). Symptoms: severe upper-abdominal pain that often radiates to the back, persistent vomiting, fever. Pain is usually 8 to 10 out of 10 and does not improve with antacids or food. Lipase blood test confirms. Stop Trulicity and seek emergency care.

2. Gallbladder disease (0.3 to 1.5%). Symptoms: right upper-quadrant pain, especially after fatty meals, often radiating to the right shoulder blade. May include nausea, vomiting, jaundice. GLP-1 medications increase the risk of gallstones, especially during rapid weight loss. Imaging confirms.

3. Severe hypoglycemia. Risk only if combined with insulin or a sulfonylurea. Symptoms: shakiness, sweating, confusion, dizziness, or loss of consciousness. Trulicity alone almost never causes hypoglycemia. The combination is the issue.

4. Acute kidney injury. Usually a downstream effect of dehydration from prolonged vomiting or diarrhea. Symptoms: dark urine, reduced urine output, dizziness, leg swelling. Patients with pre-existing kidney disease are at higher risk.

5. Severe allergic reaction (anaphylaxis). Symptoms: hives, swelling of lips/tongue/face, difficulty breathing, dizziness. Onset typically within hours of injection. Any severe allergic symptom warrants 911 and stopping Trulicity permanently.

Why side effects show up in weeks 2 to 8

Trulicity, like all GLP-1 receptor agonists, slows gastric emptying. Slower gastric emptying is the upstream cause of most GI side effects: food sits longer, the stomach distends more, the brain's nausea centers receive more signals, and intestinal contents get pushed through unevenly.

The body adapts. Receptor density on smooth muscle and on vagal nerve fibers reduces over weeks of consistent stimulation, and gastric emptying partially normalizes by week 8 to 12. This is why side effects fade for most patients on a stable dose.

The exceptions are dose escalations. Each step up resets the adaptation curve, and most patients re-experience some nausea and reduced appetite for 1 to 3 weeks after a dose increase. The pattern is predictable enough that providers often pre-warn patients.

A 2023 review (Knop et al., Lancet Diabetes Endocrinol 2023) noted that GLP-1 GI side effects follow a roughly logarithmic decay curve: most resolution happens in the first 4 to 6 weeks, with a long tail extending to 12 to 16 weeks for some patients.

Working protocols for each common symptom

The protocols below are standard recommendations from published management reviews and our medical team's clinical experience.

Nausea protocol:

• Inject in the evening so the worst nausea occurs during sleep
• Eat smaller, more frequent meals (5 to 6 over 3 large)
• Avoid fatty, fried, spicy, or sweet foods for 24 to 48 hours after injection
• Stay hydrated with small sips, ginger tea, or electrolyte drinks
• Over-the-counter: ondansetron (prescription-only) or dimenhydrinate (Dramamine)
• If nausea exceeds 5 out of 10 for more than 48 hours, contact your provider

Diarrhea protocol:

• Reduce fat and dairy temporarily
• Increase soluble fiber gradually (oats, bananas, applesauce)
• Hydrate aggressively with electrolyte solutions
• Loperamide (Imodium) for breakthrough symptoms, 2 mg per loose stool, max 8 mg/day
• If diarrhea persists more than 5 days or includes blood, contact your provider

Vomiting protocol:

• Stop solid food for 4 to 6 hours, then small bland meals (toast, rice, bananas)
• Sip electrolytes continuously
• If you cannot keep liquids down for 12+ hours, that is a dehydration risk and warrants provider contact
• Persistent vomiting beyond 24 hours is a red flag for pancreatitis or severe gastroparesis

Abdominal pain protocol:

• Mild crampy pain: heat pack, smaller meals, reduce fat
• Severe pain or pain with vomiting: emergency evaluation to rule out pancreatitis or gallbladder disease
• Pain that radiates to the back or shoulder: provider contact same day

Constipation protocol:

• Increase water to 2.5 to 3 L/day
• Increase fiber gradually (insoluble fiber: vegetables, whole grains)
• Magnesium citrate or polyethylene glycol (MiraLAX) at standard doses
• Walking 20 to 30 min/day
• If no bowel movement for 4+ days, contact your provider

Fatigue protocol:

• Audit caloric intake to ensure you are eating at least 1,200 kcal/day (women) or 1,500 kcal/day (men)
• Audit protein intake (target 0.7 g/lb of body weight)
• Check hydration
• Iron, B12, and thyroid testing if fatigue persists past week 8

Injection-site reaction protocol:

• Rotate injection sites weekly (abdomen, thigh, upper arm)
• Allow alcohol swab to fully air-dry before injecting
• Cool compress for redness or itching
• Antihistamine (cetirizine, loratadine) for persistent itching
• Persistent or worsening reactions: switch sites and contact provider

Trulicity vs other GLP-1 medications on side effects

The side-effect profiles across the GLP-1 class share more in common than they differ, but there are real distinctions.

Side effect	Trulicity (dulaglutide)	Semaglutide	Tirzepatide
Nausea	21%	16 to 44% (dose-dependent)	18 to 33%
Diarrhea	13%	9 to 30%	11 to 23%
Vomiting	13%	5 to 24%	5 to 13%
Constipation	4%	11 to 20%	6 to 11%
Discontinuation due to side effects	6 to 8%	7 to 14%	6 to 7%
Injection-site reactions	1 to 2%	<1% (Wegovy)	<1%

(Sources: AWARD trials for Trulicity; STEP and SUSTAIN trials for semaglutide; SURMOUNT and SURPASS for tirzepatide.)

Trulicity is generally considered slightly milder on nausea than semaglutide at peak doses but slightly more likely to cause modest tachycardia. Tirzepatide produces more constipation and less vomiting than the other two on average.

For patients comparing options, our GLP-1 comparison guide breaks down the practical tradeoffs.

Black-box warning: thyroid C-cell tumors

Trulicity and all GLP-1 receptor agonists carry a black-box warning for thyroid C-cell tumors. The warning is based on rodent studies showing increased medullary thyroid carcinoma (MTC) and C-cell hyperplasia in rats given GLP-1 medications.

The human relevance is unclear. Long-term human surveillance has not confirmed an increased MTC risk in clinical trials or in post-marketing data through 10+ years of widespread use (Bezin et al., Diabetes Care 2023, French nationwide cohort).

Contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

Patients in those categories should not take Trulicity, semaglutide, tirzepatide, or any other GLP-1 medication.

Pregnancy, lactation, and special populations

Pregnancy: Trulicity is not recommended during pregnancy. Animal data shows fetal effects at high doses. Patients planning pregnancy should discontinue Trulicity at least 2 months before conception (Trulicity has a long half-life).

Lactation: insufficient human data. The drug is unlikely to be absorbed by an infant if it crosses into breast milk because GLP-1 peptides are degraded in the gut, but providers typically advise alternative options.

Pediatrics: approved for type 2 diabetes in patients 10 and older. Not approved for weight management in pediatric populations.

Elderly: no dose adjustment needed for age alone. Monitor renal function and dehydration risk.

Renal impairment: Trulicity does not require dose adjustment for kidney disease, but dehydration from GI side effects can worsen kidney function. Monitor closely in patients with eGFR below 60.

Drug interactions worth knowing

Trulicity slows gastric emptying, which can affect the absorption of oral medications. The clinically relevant interactions:

• Warfarin: monitor INR closely after starting Trulicity; absorption changes can shift INR.
• Oral contraceptives: absorption may be reduced for 1 to 2 weeks after each dose increase. Backup contraception is reasonable during titration.
• Insulin and sulfonylureas: dose reduction usually needed to avoid hypoglycemia.
• Levothyroxine: absorption may be slightly reduced; monitor TSH after starting.
• Drugs requiring fast absorption (acute pain meds, some antibiotics): delayed absorption may reduce efficacy.

When to call a provider

Same day:

• Persistent vomiting >12 hours
• Severe upper-abdominal pain
• Right upper-quadrant pain after meals
• Signs of dehydration (dark urine, dizziness, decreased urination)
• Black or bloody stools
• Severe injection-site reaction

Within 24 to 48 hours:

• Nausea >5/10 not responding to anti-nausea steps
• Diarrhea >5 days despite loperamide
• Constipation >4 days despite OTC laxatives
• New rash or hives
• Sustained heart rate elevation

Routine follow-up:

• Side effects affecting quality of life past week 8
• Weight loss exceeding 2% per week sustained
• Blood-sugar lows in patients on insulin or sulfonylureas
• Any concern about dose, formulation, or alternatives

FAQ

What are the most common side effects of Trulicity? The most common side effects are nausea (21%), diarrhea (13%), vomiting (13%), abdominal pain (9%), and decreased appetite (9%), per the AWARD trial program. Most appear in weeks 1 to 4 and resolve within 8 to 12 weeks.

How long do Trulicity side effects last? Most GI side effects resolve within 4 to 12 weeks at a stable dose. Each dose escalation can cause a 1 to 3 week return of symptoms before re-adapting. Persistent side effects past 16 weeks warrant provider review.

What is the most serious side effect of Trulicity? Acute pancreatitis is the most clinically serious common-list side effect (frequency under 0.3% but severity high). The most feared theoretical risk is medullary thyroid carcinoma, which is the basis of the black-box warning, though human data has not confirmed the rodent signal.

Does Trulicity cause weight loss as a side effect? Yes. Decreased appetite is listed as a side effect in 9% of patients but is usually a desired effect. Trulicity at 4.5 mg produces about 7 to 10 pounds of weight loss in patients with type 2 diabetes (AWARD-11, Frias et al., Lancet Diabetes Endocrinol 2021).

Can Trulicity cause hair loss? Mild diffuse shedding can occur in any patient losing weight rapidly. The mechanism is telogen effluvium driven by caloric restriction, not a direct drug toxicity. Hair recovers when intake stabilizes. Adequate protein and iron help.

Why do I feel nauseated for days after my Trulicity injection? Trulicity has a long half-life (about 5 days) and steady plasma levels. Nausea is usually steady rather than acute. The first 48 hours after an injection are typically the worst, and severity drops with continued use.

Can I drink alcohol on Trulicity? You can, but alcohol amplifies nausea, vomiting, and dehydration risk, especially in the first 8 weeks. After adaptation, moderate alcohol is generally tolerated, but it remains a common trigger for breakthrough symptoms.

What should I do if I forget a dose of Trulicity? If less than 3 days late, take it as soon as you remember. If more than 3 days late, skip the missed dose and resume your normal weekly schedule. Do not double up.

Does Trulicity cause acid reflux? Yes, in some patients. Slowed gastric emptying increases pressure on the lower esophageal sphincter, allowing acid to escape into the esophagus. About 4 to 7% of patients report reflux symptoms. The protocol for managing reflux is similar to other GLP-1 medications.

Can Trulicity cause depression or mood changes? A signal exists in post-marketing surveillance, but clinical-trial data does not show an increased rate of depression at the population level. Patients with a history of mood disorders should be monitored. Any sudden mood change or suicidal ideation warrants immediate provider contact.

Is Trulicity safer than insulin? "Safer" depends on what you are comparing. Trulicity does not cause direct hypoglycemia, while insulin does. But Trulicity carries the GLP-1 class risks (pancreatitis, gallbladder, thyroid warning). For patients who can use either, GLP-1 medications generally have a more favorable side-effect profile for daily quality of life.

When should I stop taking Trulicity? Stop and seek immediate care for severe abdominal pain, persistent vomiting, signs of allergic reaction, severe gallbladder symptoms, or vision changes. Stop with provider guidance for ongoing intolerable side effects, planned pregnancy, or before certain surgeries.

Sources (numbered list, no hyperlinks needed)

1. Umpierrez G, et al. Efficacy and safety of dulaglutide in type 2 diabetes (AWARD-3). Diabetes Care. 2014;37:2168-2176.
2. Frias JP, et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg (AWARD-11). Lancet Diabetes Endocrinol. 2021;9:563-574.
3. Knop FK, et al. Gastrointestinal adverse effects of GLP-1 receptor agonists: a class review. Lancet Diabetes Endocrinol. 2023;11:431-442.
4. Bezin J, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46:384-390.
5. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
6. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
7. Eli Lilly. Trulicity (dulaglutide) prescribing information. FDA approval label, current revision.
8. American Diabetes Association. Standards of Medical Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1).
9. Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol. 2021;12:645563.
10. Storgaard H, et al. Pancreatic safety of incretin-based therapies. Diabetes Obes Metab. 2017;19:906-915.
11. Nauck MA, et al. Cardiovascular safety and benefits of GLP-1 receptor agonists. Cardiovasc Diabetol. 2017;16:152.
12. FDA Adverse Event Reporting System (FAERS). Dulaglutide post-marketing data, accessed Q1 2026.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity is a registered trademark of Eli Lilly and Company. Other brand names referenced are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.